News Archives | EUROIMMUN US

(800) 913-2022 | CONTACT PRODUCT FINDER

News

Apr 02, 2025 | News

Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test

Sep 19, 2024 | News

Oropouche Virus Disease Among U.S. Travelers – United States, 2024

Apr 29, 2024 | News

The subsidiary ProciseDx announces distribution agreement with Revvity’s EUROIMMUN US for the distribution of the ProciseDx platform in the United State and Canada

Mar 22, 2023 | News

EUROIMMUN Wins 2023 New Jersey Top Workplaces Award

Jun 24, 2021 | News

SARS-CoV-2 Variants of Concern (VOC) Alpha, Beta, Gamma and Delta

Apr 17, 2020 | News

ABC News: Largest antibody study could answer crucial coronavirus questions

Nov 20, 2018 | News

Membranous Nephropathy: Antibody-based diagnosis, prognosis, and disease monitoring

Apr 12, 2017 | News

EUROIMMUN Announces Option Agreement with Roche on Zika Virus Serology

May 28, 2016 | News

EUROIMMUN CEO Interviewed by Clinical Lab Products in regard to Zika virus

EUROIMMUN US News

EUROIMMUN US News

Apr 02, 2025

Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test

EUROIMMUN US News

Sep 19, 2024

Oropouche Virus Disease Among U.S. Travelers – United States, 2024

EUROIMMUN US News

Apr 29, 2024

The subsidiary ProciseDx announces distribution agreement with Revvity’s EUROIMMUN US for the distribution of the ProciseDx platform in the United State and Canada

EUROIMMUN US News

Mar 22, 2023

EUROIMMUN Wins 2023 New Jersey Top Workplaces Award

2025 EUROIMMUN US

Privacy Policy | Website Terms and Conditions | Cookie Notice and Settings | Consent Preferences | Sitemap